Clinigen Group plc Extended partnership agreement signed with BMS

TIDMCLIN

Clinigen Group plc

31 May 2018

RNS Reach

31 May 2018

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has signed a commercial agreement with Bristol-Myers Squibb ('BMS') in South Africa. The agreement covers BMS' South African portfolio of products for an initial period of five years.

Clinigen's Commercial Medicines business operation will provide access for patients in South Africa for the BMS products. Clinigen will provide local regulatory expertise, supply and distribution infrastructure and experience in managing licensed medicines in the region. The agreement will lead to the transfer of Marketing Authorisations (product registration certificates) from BMS to Clinigen, which will likely be completed in the first half of 2019.

In the Africa and Asia Pacific region, Clinigen has 192 actively marketed specialist pharmaceutical and medical technology licensed products, including both branded and generic products. This agreement with Bristol-Myers Squibb will complement the Group's growing basket of essential medicine on offer to healthcare providers and their patients in the region.

Shaun Chilton, Group Chief Executive Officer, Clinigen, said:

"This agreement demonstrates the long and successful relationship we have built with BMS, which began with providing access to BMS' unlicensed products globally, and has grown with Clinigen's expansion into important future growth markets.

"Clinigen is increasingly becoming the partner of choice for pharmaceutical companies to license and distribute their products. This agreement shows that our strategy for Commercial Medicines of adding regional commercial agreements to our existing portfolio of global products, a key strategic priority for the Group, is working."

- Ends -

Contact details

 
 Clinigen Group plc                  Tel: [phone] 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
 Matt Parrish, Head of Investor 
  Relations 
 
 Numis Securities Limited            Tel: [phone] 
                                      1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 
 
 RBC Capital Markets - Joint      Tel: [phone] 
  Broker                           4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners              Tel: [phone] 
                                   2020 
 Melanie Toyne-Sewell / Alex      Email: [e-mail] 
  Shaw / Deborah Bell 
 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinical Trial Services

Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.

Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides 'on demand' access globally to medicines which remain unlicensed at the point of care.

Commercial Medicines

Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

The Group also has an 'unlicensed to licensed' strategy, where it looks to take unlicensed medicines with commercial potential and licence them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.

For more information on Clinigen, please visit www.clinigengroup.com

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRALLFSEEEIIVIT

(END) Dow Jones Newswires

May 31, 2018 02:00 ET (06:00 GMT)